How do you know which vaccine research to back when a pandemic starts? Roger Highfield, Science Director, talks to Kate Bingham, former chair of the UK Government’s Vaccine Taskforce.
A traditional kind of vaccine is being readied for the fight against the COVID-19 pandemic. Roger Highfield, Science Director, finds out about Europe’s first ‘inactivated virus’ vaccine.
Roger Highfield, Science Director, talks to the scientist behind the world’s first COVID-19 vaccine that requires only a single dose.
For the first time, scientists can see a pandemic evolve in real time at the genetic level, revealing ‘variants of concern’ while guarding for large-scale genetic changes in COVID-19 that might occur by a process called recombination.
Mutant versions of the SARS-CoV-2 virus have set off alarms worldwide. Science Director Roger Highfield talks to one of the laboratories racing to find out what these variants mean for COVID-19 transmissibility and virulence, along with the development of drugs and vaccines.
The pandemic has led to the steepest slowdown in human activity since the Second World War. Science Director, Roger Highfield, asks what this means for climate change.
The UK is the first country in the world to give temporary authorisation to the Pfizer/BioNTech coronavirus vaccine for emergency pandemic use.
This is a new kind of vaccine, based on RNA, and the first approved for use in humans. Roger Highfield, Science Director, talks to Dr Berkeley Phillips, UK Medical Director of Pfizer.
Artificial intelligence, AI, has solved one of the ‘grand challenges’ of biology. Roger Highfield, Science Director, talks to John Jumper, head of the DeepMind’s landmark ‘AlphaFold’ project, about what this means for the race to combat COVID-19.
Keeper of Medicine Natasha McEnroe reflects on the addition of the first vial of COVID vaccine from a mass immunisation programme to the Science Museum Group Collection.
Details of the Oxford COVID-19 vaccine are published today, showing encouraging efficacy and some puzzling features. Science Director, Roger Highfield, talks to the trial’s Chief Investigator about the vaccine, trial regulation and a surprising bonus result.